ArnobBanerjeeMD
Oncology • North Wales, PAHematologic Oncology
Director, Clinical Research, Oncology, Janssen Pharmaceuticals
Dr. Banerjee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1400 McKean Road
North Wales, PA 19477- Is this information wrong?
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2004 - 2009- University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2004
Columbia University Vagelos College of Physicians and SurgeonsClass of 2002
Certifications & Licensure
MD State Medical License 2010 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study.Donna Catamero, Patricia Blázquez Benito, Samantha Shenoy, Margaret Doyle, Jessica Fowler, Rachel Kobos, Sandy Kruyswijk, Arnob Banerjee> ;Seminars in Oncology Nursing. 2024 Apr 9
- Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.Frerichs, K., Verkleij, C., Mateos, M., Martin, T., Rodriguez, C., Nooka, A., Banerjee, A., Chastain, K., Perales-Puchalt, A., Stephenson, T., Uhlar, C., Kobos, R., va...> ;Blood Advances. 2024 Jan 9
- Teclistamab: Mechanism of action, clinical, and translational science.Yue Guo, Natalia A Quijano Cardé, Lijuan Kang, Raluca Verona, Arnob Banerjee, Rachel Kobos, Katherine Chastain, Clarissa Uhlar, Kodandaram Pillarisetti, Margaret Doyle...> ;Clinical and Translational Science. 2024 Jan 1
- Join now to see all
Abstracts/Posters
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...Arnob Banerjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...Arnob Banerjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple MyelomaJune 7th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
